APLLTD817.00

Alembic Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMIPCALABTORNTPHARMALIVUSAKUMSAGARWALEYEADVENZYMESAARTIPHARMMcap ₹16,058 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt430.51,195.61,360.91,360.9
Net Debt310.21,112.11,164.51,164.5
Total Debt/Equity0.090.230.240.24
Net Debt/Equity0.060.210.210.21
Total Debt/EBITDA0.461.191.221.22
Net Debt/EBITDA0.331.101.041.00
Interest Coverage (EBIT/Interest)11.769.268.548.54
Total Debt/Total Capital %8.2018.7219.3619.36
As Filed — company-reported covenants
Debt/Equity (as filed)0.230.240.28
Debt Service Coverage (as filed)9.986.917.63
Interest Service Coverage (as filed)9.988.419.04
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.